Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1Phase 1 1

Status

Completed 17Recruiting 6Unknown 4Withdrawn 3Terminated 3Suspended 3Active not recruiting 2

Sponsor Class

OTHER 3INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 6Observational 3

Sponsor

Cancer Type

Tumor-Agnostic 2Gynecologic 2Lymphoid 1Gastrointestinal 1

Conditions

Neoplasms 2Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Endometrial Neoplasms 1

Interventions

pembrolizumab 551Specimen Handling 465Carboplatin 441Magnetic Resonance Spectroscopy 430Cyclophosphamide 412Cisplatin 397Radiotherapy 313Gemcitabine 309Bevacizumab 307Paclitaxel 294Biopsy 261Drug Therapy 249Capecitabine 242Oxaliplatin 239fludarabine 237Nivolumab 224venetoclax 219Injections 213Docetaxel 205Fluorouracil 203Dexamethasone 187Radiosurgery 172Rituximab 158Pemetrexed 153Standard of Care 146durvalumab 143Leucovorin 139atezolizumab 138toripalimab 134tislelizumab 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Interventional × Antibodies, Monoclonal × Clear all
NCT06366347 2026-02-11

ALPINE: Maintenance Letrozole/Abemaciclib

Dana-Farber Cancer Institute

Phase 2 Recruiting
32 enrolled
Gynecologic

Endometrial Neoplasms

NCT06840119 2026-01-28

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Immunocore Ltd

Phase 1/2 Recruiting
600 enrolled
Tumor-Agnostic

Neoplasms

NCT06550141 2025-11-14

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Massachusetts General Hospital

Phase 2 Recruiting
28 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05462496 2024-10-15

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

Icahn School of Medicine at Mount Sinai

Phase 2 Recruiting
25 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06274437 2024-08-07

A Study of BND-35 in Participants With Advanced Solid Tumors

Biond Biologics

Phase 1 Recruiting
280 enrolled
Tumor-Agnostic

Neoplasms

NCT06455072 2024-06-12

Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

Fujian Cancer Hospital

Phase 2 Recruiting
37 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡